Clinical Trial Update: Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib with toripalimab for refractory metastatic digestive system carcinoma and primary peritoneal cancer is ongoing (status unkn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Carcinoma
• Peritoneal Cancer

Drugs mentioned

• Surufatinib (Surufatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking University | Conditions: Refractory Metastatic Digestive System Carcinoma, Primary Peritoneal Cancer | Phase 2 | Status: UNKNOWN